ACAD
36.83
+0.2
+0.55%
AEMD
7.41
-0.18
-2.37%
APRI
1.78
+0.08
+4.71%
ARNA
2.639
-0.071
-2.620%
ATEC
0.58
0.00
+0.87%
CNAT
3.74
-0.19
-4.83%
CRXM
0.28
-0.09
-24.33%
CYTX
0.381
+0.019
+5.1643%
DXCM
89.71
-4.43
-4.71%
GNMK
10.03
-0.31
-3.00%
HALO
17.19
-0.27
-1.55%
ILMN
196.14
-1.47
-0.74%
INNV
0.148
0.00
0.00%
INO
7.28
-0.21
-2.80%
ISCO
3.76
-0.14
-3.59%
ISIS
48.83
-1.35
-2.69%
LGND
90.4
-1.54
-1.68%
LPTN
0.24
+0.01
+4.3043%
MBVX
1.74
-0.01
-0.57%
MEIP
1.835
+0.015
+0.824%
MNOV
3.05
+0.1
+3.39%
MRTX
26.47
+0.65
+2.52%
MSTX
0.48
-0.005
-1.0103%
NBIX
46.9
+0.52
+1.12%
NUVA
52.06
-0.66
-1.25%
ONCS
5.64
+0.26
+4.83%
ONVO
2.56
-0.17
-6.23%
OREX
2.71
-0.06
-2.17%
OTIC
21.31
-1.36
-6.00%
QDEL
20.275
-0.315
-1.530%
RCPT
231.96
0.00
0.00%
RGLS
8.33
0.00
0.00%
RMD
51.15
-0.79
-1.52%
SCIE
0.014
0.00
0.00%
SPHS
0.88
-0.02
-2.22%
SRNE
12.7
+0.02
+0.16%
TROV
5.72
-0.23
-3.87%
VICL
0.591
+0.001
+0.1525%
VOLC
18
0.00
0.00%
ZGNX
18.88
-0.34
-1.77%
ACAD
36.83
+0.2
+0.55%
AEMD
7.41
-0.18
-2.37%
APRI
1.78
+0.08
+4.71%
ARNA
2.639
-0.071
-2.620%
ATEC
0.58
0.00
+0.87%
CNAT
3.74
-0.19
-4.83%
CRXM
0.28
-0.09
-24.33%
CYTX
0.381
+0.019
+5.1643%
DXCM
89.71
-4.43
-4.71%
GNMK
10.03
-0.31
-3.00%
HALO
17.19
-0.27
-1.55%
ILMN
196.14
-1.47
-0.74%
INNV
0.148
0.00
0.00%
INO
7.28
-0.21
-2.80%
ISCO
3.76
-0.14
-3.59%
ISIS
48.83
-1.35
-2.69%
LGND
90.4
-1.54
-1.68%
LPTN
0.24
+0.01
+4.3043%
MBVX
1.74
-0.01
-0.57%
MEIP
1.835
+0.015
+0.824%
MNOV
3.05
+0.1
+3.39%
MRTX
26.47
+0.65
+2.52%
MSTX
0.48
-0.005
-1.0103%
NBIX
46.9
+0.52
+1.12%
NUVA
52.06
-0.66
-1.25%
ONCS
5.64
+0.26
+4.83%
ONVO
2.56
-0.17
-6.23%
OREX
2.71
-0.06
-2.17%
OTIC
21.31
-1.36
-6.00%
QDEL
20.275
-0.315
-1.530%
RCPT
231.96
0.00
0.00%
RGLS
8.33
0.00
0.00%
RMD
51.15
-0.79
-1.52%
SCIE
0.014
0.00
0.00%
SPHS
0.88
-0.02
-2.22%
SRNE
12.7
+0.02
+0.16%
TROV
5.72
-0.23
-3.87%
VICL
0.591
+0.001
+0.1525%
VOLC
18
0.00
0.00%
ZGNX
18.88
-0.34
-1.77%
Home » Bio: Melinda Richter

Bio: Melinda Richter

As Head of Janssen Labs, Melinda fosters Johnson & Johnson’s external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, Janssen Labs is the best place to start a biotech company.
Prior to joining Janssen Labs, Melinda was Founder and CEO of Prescience International, an award winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set-out to create a better model, which now forms the basis for Janssen Labs’ operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also started, raised capital and did large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and an MBA from INSEAD in France.